Targeting dormant leukaemia cells
Nature
May 12, 2008
A new role for a protein involved in leukaemia is described in Nature this week; the research demonstrates its potential as a therapeutic target to eradicate dormant leukaemia-initiating cells.
The promyelocytic leukaemia protein (PML) tumour suppressor is known to be involved in the development of some forms of leukaemia. Pier Paolo Pandolfi and colleagues identify a new and unexpected role for PML in the maintenance of both haematopoietic stem cells and leukaemia-initiating cells. They demonstrate, in mice, that targeting the protein with arsenic trioxide eliminates the cancer-initiating cells, thought to be resistant to chemotherapy and other therapies.
The team believes that their results present a new pharmacological approach to target cells that are missed by other therapies and therefore lead to disease relapse.
doi: 10.1038/nature07016
Research highlights
-
Jun 11
Engineering: Earmuffs measure blood alcohol levels through the skinScientific Reports
-
Jun 10
Computer science: Artificial intelligence speeds up computer chip designNature
-
Jun 2
Physics: Modelling improvements to ride-sharing adoptionNature Communications
-
May 27
Physics: Universal patterns in the way people moveNature
-
May 20
Astrophysics: Nickel detected in 2I/Borisov and comets from our Solar SystemNature
-
May 4
Biomedical engineering: Sound compression in hearing aids may make them worseNature Biomedical Engineering
